Dergiler / Nöropsikiyatri Arşivi / 2019 / Cilt: 56 - Sayı: 2

Familial Amyloid Polyneuropathy

Familyal Amiloid Polinöropatisi

Sayfa
150–156
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Early initiation of the treatment is important for better functional outcome.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is a life-threatening disease caused by the accumulation of amyloidogenic transthyretin (TTR) protein in tissues.
📊
Temel Bulgular & Veri:Routine follow-up should include a wide range of tests to demonstrate systemic involvement.
💡
Sonuç & Katkı:Early initiation of the treatment is important for better functional outcome.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is a life-threatening disease caused by the accumulation of amyloidogenic transthyretin (TTR) protein in tissues. Mutations in TTR gene destabilize TTR protein to misfold from its native tetramer form to amyloidogenic monomer form. In endemic countries, TTR-FAP presents with lengthdependent small fiber neuropathy, however in non-endemic countries clinical features can be highly variable. Genetic testing for TTR gene is mandatory for the diagnosis. Demonstrating amyloid deposits in tissues may be necessary for distinguishing symptomatic patients from asymptomatic carriers. Routine follow-up should include a wide range of tests to demonstrate systemic involvement. In recent years, treatment of TTR-FAP has significantly improved with new therapeutic approaches. TTR stabilizers and TTR-gene silencing drugs prevent the progression of the disease. Monoclonal antibodies that target amyloid deposits are currently under development. Early initiation of the treatment is important for better functional outcome.

Abstract

Transtretin ilişkili ailevi amiloid polinöropatisi (TİAAP) dokularda amiloidojenik transtretin (TTR) proteini birikimi nedenli, hayatı tehdit eden bir hastalıktır. TTR genindeki mutasyonlar, TTR proteinini destabilize ederek doğal olan tetramer formun amiloidojenik monomer forma dönüşmesine neden olur. TİAAP endemik ülkelerde uzunluğa bağlı ince lif nöropatisi olarak bulgu verir, ancak endemik olmayan ülkelerde klinik özellikler ciddi farklılıklar gösterebilmektedir. TTR genine yönelik genetik test tanı için esastır. Dokularda amiloid depolanmasının gösterilmesi ise asemptomatik taşıyıcılar ile semptomatik bireylerin ayrımında gerekli olabilmektedir. Sistemik tutulumun gösterilebilmesi amacıyla rutin takip, geniş bir test listesini içermelidir. Son yıllarda TİAAP tedavisinde, yeni ilaç alternatiflerinin ortaya çıkmasıyla belirgin aşama kaydedilmiştir. TTR stabilizatörleri ve TTR gen susturucu tedaviler hastalığın ilerlemesini engellemektedir. Amiloid birikimlerini hedef alan monoklonal antikorlar şu anda geliştirilme aşamasındadır. Erken tedavi, hastaların fonksiyonel durumu açısından önem taşımaktadır.

🔖

Bu Makaleye Atıf Yap

ÇAKAR, A., TEKÇE, H. D., PARMAN, Y. (2019). Familial Amyloid Polyneuropathy. Nöropsikiyatri Arşivi, Cilt: 56 - Sayı: 2, 150–156. https://ajindex.com/articles/292215

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Andrade C. A peculiar form of peripheral neuropathy
  2. familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952
  3. 408–427. [CrossRef] 2. Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med 2015
  4. 625–638. [CrossRef] 3. Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014
  5. 1227– 1233. [CrossRef] 4. Freeman R, Barroso F. Recent advances in familial amyloid polyneuropathy. Curr Opin Neurol 2015
  6. 494–499. [CrossRef] 5. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 2018
  7. [CrossRef] 6. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, Coelho T. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016
  8. 29 Suppl 1:S3–S13. [CrossRef] 7. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M. Longterm survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012
  9. 637–643. [CrossRef] 8. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012
  10. 152–158. [CrossRef] 9. Durmus-Tekce H, Matur Z, Mert Atmaca M, Poda M, Cakar A, Hidir Ulas U, Oflazer-Serdaroglu P, Deymeer F, Parman YG. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTRFAP) in Turkey. Neuromuscul Disord 2016
  11. 441–446. [CrossRef] 10. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001
  12. 647–657. [CrossRef] 11. Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013
  13. 129–139. [CrossRef] 12. Sahin E, Cakar A, Durmus-Tekce H, Parman Y. A Val30Met sporadic familial amyloid polyneuropathy case with atypical presentation: upper limb onset of symptoms. Acta Neurol Belg 2018. [CrossRef] 13. Suanprasert N,